- Saturday, April 1, 2023
7:00 AM – 8:00 AM
CE Symposia: Continuing the Conversation in Relapsed/Refractory Diffuse Large B-Cell Lymphoma: Addressing Operational Challenges and Integrating New and Emerging Antibody-Based Regimens
7:00 AM – 8:00 AM
CE Symposia: Continuing the Conversation in Relapsed/Refractory Diffuse Large B-Cell Lymphoma: Addressing Operational Challenges and Integrating New and Emerging Antibody-Based RegimensLocation: 159*Speaker: – Duquesne University School of Pharmacy
*Speaker: – Emory Healthcare - Winship Cancer Institute
*Speaker: – University of Michigan Rogel Cancer Center
Karen Fancher, PharmD, BCOP – Duquesne University School of Pharmacy ### 894757###*Speaker###Assistant Professor of Pharmacy Practice###Duquesne University School of Pharmacy###*Speaker: – Duquesne University School of Pharmacy
### @@@ Arpita Gandhi, PharmD, BCOP – Emory Healthcare - Winship Cancer Institute ### 1774202###*Speaker###Hematology/Oncology Clinical Pharmacy Specialist###Emory Healthcare - Winship Cancer Institute###*Speaker: – Emory Healthcare - Winship Cancer Institute
### @@@ Victoria R. Nachar, PharmD, BCOP – University of Michigan Rogel Cancer Center ### 1094223###*Speaker###Clinical Pharmacist###University of Michigan Rogel Cancer Center###*Speaker: – University of Michigan Rogel Cancer Center
### 7:00 AM – 8:00 AM
CE Symposia: Optimizing Outcomes for Older Patients With Acute Myeloid Leukemia: A Focus on Alternative Induction Regimens and Maintenance Therapy
7:00 AM – 8:00 AM
CE Symposia: Optimizing Outcomes for Older Patients With Acute Myeloid Leukemia: A Focus on Alternative Induction Regimens and Maintenance Therapy Location: 158*Speaker: – NewYork-Presbyterian Hospital, Columbia University Irving Medical Center
*Speaker: – St Luke's Cancer Institute
*Speaker: – University of Texas MD Anderson Cancer Center
Peter Campbell, PharmD, MBA, BCOP – NewYork-Presbyterian Hospital, Columbia University Irving Medical Center ### 1589099###*Speaker######NewYork-Presbyterian Hospital, Columbia University Irving Medical Center###*Speaker: – NewYork-Presbyterian Hospital, Columbia University Irving Medical Center
### @@@ Robert S. Mancini, PharmD, BCOP, FHOPA – St Luke's Cancer Institute ### 1486422###*Speaker###BMT Pharmacy Program Coordinator and PGY2 Residency Director###St Luke's Cancer Institute###*Speaker: – St Luke's Cancer Institute
### @@@ Kayleigh R. Marx, PharmD, BCOP – University of Texas MD Anderson Cancer Center ### 1247573###*Speaker###Clinical Pharmacy Specialist, Leukemia###University of Texas MD Anderson Cancer Center###*Speaker: – University of Texas MD Anderson Cancer Center
### 8:00 AM – 9:00 AM
How Do I Compare? Results of the Oncology Practice Landscape Survey from the Practice Outcomes and Professional Benchmarking Committee
8:00 AM – 9:00 AM
402 - How Do I Compare? Results of the Oncology Practice Landscape Survey from the Practice Outcomes and Professional Benchmarking CommitteeLocation: 160-163Co-Speaker: – University of California, Irvine
Co-Speaker: – Memorial Sloan Kettering Cancer Center
Co-Speaker: – Roswell Park Comprehensive Cancer Center
Practice Management
Shawn P. Griffin, PharmD, BCOP (he/him/his) – University of California, Irvine ### 1772980###Co-Speaker###Assistant Clinical Professor###University of California, Irvine###Co-Speaker: – University of California, Irvine
### he/him/his @@@ Stephen Harnicar, PharmD, BCOP (he/him/his) – Memorial Sloan Kettering Cancer Center ### 1806654###Co-Speaker###Manager, Clinical Pharmacy Practice & Research###Memorial Sloan Kettering Cancer Center###Co-Speaker: – Memorial Sloan Kettering Cancer Center
### he/him/his @@@ Grazyna Riebandt, PharmD, BCOP (she/her/hers) – Roswell Park Comprehensive Cancer Center ### 1806655###Co-Speaker###Clinical Pharmacy Services Director###Roswell Park Comprehensive Cancer Center###Co-Speaker: – Roswell Park Comprehensive Cancer Center
### she/her/hers
8:00 AM – 9:00 AM
Postmarketing Safety in Oncology: An Overview of Pharmacovigilance at the FDA
8:00 AM – 9:00 AM
401 - Postmarketing Safety in Oncology: An Overview of Pharmacovigilance at the FDALocation: BallroomSpeaker: – U.S. Food and Drug Administration
Practice Management
Lauren McBride, PharmD, BCOP, FHOPA (she/her/hers) – U.S. Food and Drug Administration ### 1486421###Speaker###Oncology Safety Evaluator###U.S. Food and Drug Administration###Speaker: – U.S. Food and Drug Administration
### she/her/hers
9:00 AM – 10:00 AM
Blast Off! A Review of Monoclonal Antibodies in Neuroblastoma Treatment (Pediatric Pearls Part 4)
9:00 AM – 10:00 AM
404 - Blast Off! A Review of Monoclonal Antibodies in Neuroblastoma Treatment (Pediatric Pearls Part 4)Location: 160-163Speaker: – Dartmouth Health
Pediatrics
Caitlin R. Harper, PharmD (she/her/hers) – Dartmouth Health ### 1810347###Speaker###Hematology/Oncology Clinical Pharmacist###Dartmouth Health###Speaker: – Dartmouth Health
### she/her/hers
9:00 AM – 10:00 AM
High Impact Pharmacogenomics in Pediatrics (Pediatric Pearls Part 3)
9:00 AM – 10:00 AM
404 - High Impact Pharmacogenomics in Pediatrics (Pediatric Pearls Part 3)Location: 160-163Pediatrics
Cathryn Jennissen, PharmD, BCOP – OneOme ### 1810346###Speaker###Senior Clinical Pharmacist ###OneOme###Speaker: – OneOme
###
9:00 AM – 10:00 AM
Investigational Drug Updates: Intratumoral Injections Bring Cancer Treatment Local
9:00 AM – 10:00 AM
405 - Investigational Drug Updates: Intratumoral Injections Bring Cancer Treatment Local Location: 164-167Speaker: – The Ohio State University Wexner Medical Center and James Cancer Hospital
Hallie Barr, PharmD, MBA, BCOP (she/her/hers) – The Ohio State University Wexner Medical Center and James Cancer Hospital ### 1390143###Speaker###Pharmacy Manager, Investigational Drug Service###The Ohio State University Wexner Medical Center and James Cancer Hospital###Speaker: – The Ohio State University Wexner Medical Center and James Cancer Hospital
### she/her/hers
9:00 AM – 10:00 AM
Position Justifications: Justifying the Return on Investment
9:00 AM – 10:00 AM
403 - Position Justifications: Justifying the Return on InvestmentLocation: BallroomSpeaker: – University of Kansas Cancer Center
Practice Management
Zahra Mahmoudjafari, PharmD, MBA, BCOP (she/her/hers) – University of Kansas Cancer Center ### 958456###Speaker###Clinical Pharmacy Manager-Hem/BMT/CAR-T###University of Kansas Cancer Center###Speaker: – University of Kansas Cancer Center
### she/her/hers
9:00 AM – 10:00 AM
SOS…Defibrotide Prophylaxis for the Prevention of Sinusoidal Obstruction Syndrome in pediatric stem cell (Pediatric Pearls Part 1)
9:00 AM – 10:00 AM
404 - SOS…Defibrotide Prophylaxis for the Prevention of Sinusoidal Obstruction Syndrome in pediatric stem cell (Pediatric Pearls Part 1) Location: 160-163Speaker: – Childrens National Hospital
Pediatrics
Radha Rohatgi, Pharm.D, BCOP (she/her/hers) – Childrens National Hospital ### 1810348###Speaker###BMT Clinical Pharmacy Specialist###Childrens National Hospital###Speaker: – Childrens National Hospital
### she/her/hers
9:00 AM – 10:00 AM
Spare a Thought for Asparaginase: Updates on Asparaginase (Pediatric Pearls Part 2)
9:00 AM – 10:00 AM
404 - Spare a Thought for Asparaginase: Updates on Asparaginase (Pediatric Pearls Part 2) Location: 160-163Speaker: – Children's Hospital Colorado
Pediatrics
Zanette Kanani Bradley, PharmD, BCOP (she/her/hers) – Children's Hospital Colorado ### 1810345###Speaker###Pediatric Ambulatory Oncology Clinical Pharmacy Specialist###Children's Hospital Colorado###Speaker: – Children's Hospital Colorado
### she/her/hers
10:15 AM – 11:15 AM
Updates in Amyloidosis
10:15 AM – 11:15 AM
406 - Updates in AmyloidosisLocation: 160-163Speaker: – Lymphoma Program and Lymphoma Translational Research, Department of Pharmacy, Abramson Cancer Center at the Hospital of the University of Pennsylvania
Mitchell E. Hughes, Pharm.D., BCOP (he/him/his) – Lymphoma Program and Lymphoma Translational Research, Department of Pharmacy, Abramson Cancer Center at the Hospital of the University of Pennsylvania ### 1774217###Speaker###Clinical Pharmacist Specialist, Hematology/Oncology/Cellular Therapy###Lymphoma Program and Lymphoma Translational Research, Department of Pharmacy, Abramson Cancer Center at the Hospital of the University of Pennsylvania###Speaker: – Lymphoma Program and Lymphoma Translational Research, Department of Pharmacy, Abramson Cancer Center at the Hospital of the University of Pennsylvania
### he/him/his
10:15 AM – 11:30 AM
What's New Down Under; Updates in Gynecologic Malignancy
10:15 AM – 11:30 AM
BC7 - What's New Down Under? Updates in Gynecologic MalignancyLocation: BallroomSpeaker: – Stephenson Cancer Center at OU Health
Co-Speaker: – Medical University of South Carolina
BCOP
Sarah K. Hayward, PharmD, BCOP – Stephenson Cancer Center at OU Health ### 1774203###Speaker###Clinical Pharmacy Specialist, Gynecologic Oncology###Stephenson Cancer Center at OU Health###Speaker: – Stephenson Cancer Center at OU Health
### @@@ Jennifer MacDonald, PharmD, BCOP – Medical University of South Carolina ### 1774204###Co-Speaker###Clinical Pharmacy Specialist- Gynecologic Oncology###Medical University of South Carolina###Co-Speaker: – Medical University of South Carolina
###
12:00 PM – 12:45 PM
Non-CE Symposia: Expanded Horizons: A Post-endocrine Option for Patients with HR+/HER2- mBC
12:00 PM – 12:45 PM
Non-CE Symposia: Expanded Horizons: A Post-endocrine Option for Patients with HR+/HER2- mBC Location: 159
Anne O'Dea, MD ### 1896158###*Speaker#########*Speaker:
### 12:00 PM – 12:45 PM
Non-CE Symposia: Time TBD (AbbVie)
12:00 PM – 12:45 PM
Non-CE Symposia: Pivotal Phase 3 Data in Newly Diagnosed AMLLocation: 158
Rami Komrokji, MD ### 957893###*Speaker#########*Speaker:
###
